Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors

Seung Yul Lee, Myeongki Hong, Dong Ho Shin, Jung Sun Kim, Byeong Keuk Kim, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Hyo Soo Kim, Marco Valgimigli, Tullio Palmerini, Gregg W. Stone

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation has not been established yet. The objectives of this study were to evaluate the optimal duration of DAPT after the DES implantation. Methods: From three randomized controlled trials investigating DAPT duration after coronary stent implantation, we evaluated the clinical outcomes of short-term (6 months or less) DAPT compared with prolonged DAPT (12 months or more) in 1661 DES-treated pairs matched by propensity scores. At follow-up of 1 year, net adverse clinical event (NACE) was defined as cardiac death, myocardial infarction, target vessel revascularization, definite/probable stent thrombosis, or thrombolysis in myocardial infarction major bleeding. Results: Short-term DAPT as compared with prolonged DAPT was not associated with 1-year NACEs after DES implantation [hazard ratio (HR) 1.068, 95 % confidence interval (CI) 0.787–1.450, p = 0.671]. Predictors for NACEs were old age (>75 years), hypertension, diabetes mellitus, renal dysfunction (serum creatinine ≥2.0 mg/dL), and multi-vessel disease. The DAPT strategy differentially contributed to the occurrence of NACEs according to the risk burden (p for interaction <0.001). In patients with low risk for NACEs, bleeding events were less in short-term DAPT than in prolonged DAPT (HR 0.332, 95 % CI 0.130–0.849, p = 0.021) (p for interaction = 0.098). Meanwhile, short-term DAPT was associated with more ischemic events that included cardiac death, myocardial infarction, target vessel revascularization, or definite/probable stent thrombosis (HR 2.164, 95 % CI 1.340–3.494, p = 0.002) (p for interaction <0.001) in patients with high risk for NACEs. Conclusion: One-year clinical outcomes of DAPT after DES implantation depended on the burden of cardiovascular risk.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalClinical Research in Cardiology
Volume106
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Drug-Eluting Stents
Therapeutics
Stents
Myocardial Infarction
Confidence Intervals
Thrombosis
Hemorrhage
Propensity Score
Creatinine
Diabetes Mellitus
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Seung Yul ; Hong, Myeongki ; Shin, Dong Ho ; Kim, Jung Sun ; Kim, Byeong Keuk ; Ko, Young Guk ; Choi, Donghoon ; Jang, Yangsoo ; Kim, Hyo Soo ; Valgimigli, Marco ; Palmerini, Tullio ; Stone, Gregg W. / Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. In: Clinical Research in Cardiology. 2017 ; Vol. 106, No. 3. pp. 165-173.
@article{38a789d9229b4cf688ebc41af907b1b3,
title = "Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors",
abstract = "Background: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation has not been established yet. The objectives of this study were to evaluate the optimal duration of DAPT after the DES implantation. Methods: From three randomized controlled trials investigating DAPT duration after coronary stent implantation, we evaluated the clinical outcomes of short-term (6 months or less) DAPT compared with prolonged DAPT (12 months or more) in 1661 DES-treated pairs matched by propensity scores. At follow-up of 1 year, net adverse clinical event (NACE) was defined as cardiac death, myocardial infarction, target vessel revascularization, definite/probable stent thrombosis, or thrombolysis in myocardial infarction major bleeding. Results: Short-term DAPT as compared with prolonged DAPT was not associated with 1-year NACEs after DES implantation [hazard ratio (HR) 1.068, 95 {\%} confidence interval (CI) 0.787–1.450, p = 0.671]. Predictors for NACEs were old age (>75 years), hypertension, diabetes mellitus, renal dysfunction (serum creatinine ≥2.0 mg/dL), and multi-vessel disease. The DAPT strategy differentially contributed to the occurrence of NACEs according to the risk burden (p for interaction <0.001). In patients with low risk for NACEs, bleeding events were less in short-term DAPT than in prolonged DAPT (HR 0.332, 95 {\%} CI 0.130–0.849, p = 0.021) (p for interaction = 0.098). Meanwhile, short-term DAPT was associated with more ischemic events that included cardiac death, myocardial infarction, target vessel revascularization, or definite/probable stent thrombosis (HR 2.164, 95 {\%} CI 1.340–3.494, p = 0.002) (p for interaction <0.001) in patients with high risk for NACEs. Conclusion: One-year clinical outcomes of DAPT after DES implantation depended on the burden of cardiovascular risk.",
author = "Lee, {Seung Yul} and Myeongki Hong and Shin, {Dong Ho} and Kim, {Jung Sun} and Kim, {Byeong Keuk} and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Kim, {Hyo Soo} and Marco Valgimigli and Tullio Palmerini and Stone, {Gregg W.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00392-016-1035-4",
language = "English",
volume = "106",
pages = "165--173",
journal = "Clinical Research in Cardiology",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "3",

}

Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. / Lee, Seung Yul; Hong, Myeongki; Shin, Dong Ho; Kim, Jung Sun; Kim, Byeong Keuk; Ko, Young Guk; Choi, Donghoon; Jang, Yangsoo; Kim, Hyo Soo; Valgimigli, Marco; Palmerini, Tullio; Stone, Gregg W.

In: Clinical Research in Cardiology, Vol. 106, No. 3, 01.03.2017, p. 165-173.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors

AU - Lee, Seung Yul

AU - Hong, Myeongki

AU - Shin, Dong Ho

AU - Kim, Jung Sun

AU - Kim, Byeong Keuk

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Kim, Hyo Soo

AU - Valgimigli, Marco

AU - Palmerini, Tullio

AU - Stone, Gregg W.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation has not been established yet. The objectives of this study were to evaluate the optimal duration of DAPT after the DES implantation. Methods: From three randomized controlled trials investigating DAPT duration after coronary stent implantation, we evaluated the clinical outcomes of short-term (6 months or less) DAPT compared with prolonged DAPT (12 months or more) in 1661 DES-treated pairs matched by propensity scores. At follow-up of 1 year, net adverse clinical event (NACE) was defined as cardiac death, myocardial infarction, target vessel revascularization, definite/probable stent thrombosis, or thrombolysis in myocardial infarction major bleeding. Results: Short-term DAPT as compared with prolonged DAPT was not associated with 1-year NACEs after DES implantation [hazard ratio (HR) 1.068, 95 % confidence interval (CI) 0.787–1.450, p = 0.671]. Predictors for NACEs were old age (>75 years), hypertension, diabetes mellitus, renal dysfunction (serum creatinine ≥2.0 mg/dL), and multi-vessel disease. The DAPT strategy differentially contributed to the occurrence of NACEs according to the risk burden (p for interaction <0.001). In patients with low risk for NACEs, bleeding events were less in short-term DAPT than in prolonged DAPT (HR 0.332, 95 % CI 0.130–0.849, p = 0.021) (p for interaction = 0.098). Meanwhile, short-term DAPT was associated with more ischemic events that included cardiac death, myocardial infarction, target vessel revascularization, or definite/probable stent thrombosis (HR 2.164, 95 % CI 1.340–3.494, p = 0.002) (p for interaction <0.001) in patients with high risk for NACEs. Conclusion: One-year clinical outcomes of DAPT after DES implantation depended on the burden of cardiovascular risk.

AB - Background: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation has not been established yet. The objectives of this study were to evaluate the optimal duration of DAPT after the DES implantation. Methods: From three randomized controlled trials investigating DAPT duration after coronary stent implantation, we evaluated the clinical outcomes of short-term (6 months or less) DAPT compared with prolonged DAPT (12 months or more) in 1661 DES-treated pairs matched by propensity scores. At follow-up of 1 year, net adverse clinical event (NACE) was defined as cardiac death, myocardial infarction, target vessel revascularization, definite/probable stent thrombosis, or thrombolysis in myocardial infarction major bleeding. Results: Short-term DAPT as compared with prolonged DAPT was not associated with 1-year NACEs after DES implantation [hazard ratio (HR) 1.068, 95 % confidence interval (CI) 0.787–1.450, p = 0.671]. Predictors for NACEs were old age (>75 years), hypertension, diabetes mellitus, renal dysfunction (serum creatinine ≥2.0 mg/dL), and multi-vessel disease. The DAPT strategy differentially contributed to the occurrence of NACEs according to the risk burden (p for interaction <0.001). In patients with low risk for NACEs, bleeding events were less in short-term DAPT than in prolonged DAPT (HR 0.332, 95 % CI 0.130–0.849, p = 0.021) (p for interaction = 0.098). Meanwhile, short-term DAPT was associated with more ischemic events that included cardiac death, myocardial infarction, target vessel revascularization, or definite/probable stent thrombosis (HR 2.164, 95 % CI 1.340–3.494, p = 0.002) (p for interaction <0.001) in patients with high risk for NACEs. Conclusion: One-year clinical outcomes of DAPT after DES implantation depended on the burden of cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=84986253427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986253427&partnerID=8YFLogxK

U2 - 10.1007/s00392-016-1035-4

DO - 10.1007/s00392-016-1035-4

M3 - Article

C2 - 27631821

AN - SCOPUS:84986253427

VL - 106

SP - 165

EP - 173

JO - Clinical Research in Cardiology

JF - Clinical Research in Cardiology

SN - 1861-0684

IS - 3

ER -